{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T08:02:55Z","timestamp":1795161775681,"version":"4.10.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jacc.2019.09.022","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T15:54:53Z","timestamp":1573487693000},"page":"2511-2524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection"],"prefix":"10.1016","volume":"74","author":[{"given":"David Z.","family":"Cherney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodele","family":"Odutayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.09.022_bib1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes","volume":"172","author":"Coca","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib2","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2019.09.022_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacc.2019.09.022_bib4","first-page":"1","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","author":"Papademetriou","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.09.022_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"JASN"},{"key":"10.1016\/j.jacc.2019.09.022_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","article-title":"Diabetes with early kidney involvement may shorten life expectancy by 16 years","volume":"92","author":"Wen","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.09.022_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.09.022_bib9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.09.022_bib10","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2019.09.022_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.09.022_bib12","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.2337\/dc18-0394","article-title":"Acute effect of empagliflozin on fractional excretion of sodium and eGFR in youth with type 2 diabetes","volume":"41","author":"Bjornstad","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.09.022_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.09.022_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.09.022_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.09.022_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10157-018-1673-0","article-title":"Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials","volume":"23","author":"Kuriyama","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jacc.2019.09.022_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11892-018-1038-9","article-title":"SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials","volume":"18","author":"Jia","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacc.2019.09.022_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/jim-2017-000445","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes","volume":"65","author":"Yoshimoto","year":"2017","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.09.022_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.09.022_bib21","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/14656566.2016.1201073","article-title":"Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors","volume":"17","author":"Filippatos","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacc.2019.09.022_bib22","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.09.022_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.09.022_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.09.022_bib26","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.09.022_bib27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.09.022_bib28","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jacc.2019.09.022_bib29","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.09.022_bib30","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.09.022_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.09.022_bib32","first-page":"844","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.jacc.2019.09.022_bib33","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1139\/cjpp-2018-0359","article-title":"Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications","volume":"96","author":"Kumar","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jacc.2019.09.022_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.kint.2018.05.026","article-title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials","volume":"94","author":"van Raalte","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.09.022_bib35","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib39","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jcjd.2017.11.004","article-title":"Chronic kidney disease in diabetes","volume":"42 Suppl 1","author":"McFarlane","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jacc.2019.09.022_bib40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7326\/L19-0320","article-title":"Fracture risk after initiation of use of canagliflozin","volume":"171","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib42","first-page":"575","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jacc.2019.09.022_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.09.022_bib44","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","article-title":"Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale","volume":"9","author":"Kubota","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacc.2019.09.022_bib45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fendo.2018.00421","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2019.09.022_bib46","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.09.022_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2019.09.022_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1253\/circj.CJ-16-1148","article-title":"Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease\u2015results from EMPA-REG OUTCOME","volume":"81","author":"Kaku","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2019.09.022_bib49","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s00125-018-4630-2","article-title":"Empagliflozin in women with type 2 diabetes and cardiovascular disease\u2014an analysis of EMPA-REG OUTCOME","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.09.022_bib50","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.09.022_bib51","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.09.022_bib52","first-page":"703","article-title":"Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective","volume":"20","author":"Stafylas","year":"2007","journal-title":"J.\u00a0Nephrol"},{"key":"10.1016\/j.jacc.2019.09.022_bib53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib54","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2019.09.022_bib55","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.2337\/dc19-S011","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes\u20132019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.09.022_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cmet.2019.04.011","article-title":"A\u00a0big win for diabetic kidney disease: CREDENCE","volume":"29","author":"Cherney","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2019.09.022_bib57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MNH.0000000000000214","article-title":"New and old agents in the management of diabetic nephropathy","volume":"25","author":"Lytvyn","year":"2016","journal-title":"Curr Opinion Nephrol Hyperten"},{"key":"10.1016\/j.jacc.2019.09.022_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium\u2013glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107","year":"2015","journal-title":"Curr Opinion Nephrol Hyperten"},{"key":"10.1016\/j.jacc.2019.09.022_bib59","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.09.022_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.09.022_bib61","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719377289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719377289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:25:30Z","timestamp":1760016330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719377289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":61,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0735109719377289"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.09.022","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}